Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) - Trial NCT06337162
Access comprehensive clinical trial information for NCT06337162 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abramson Cancer Center at Penn Medicine and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Abramson Cancer Center at Penn Medicine
Timeline & Enrollment
Phase 1
May 01, 2024
Sep 01, 2028
Primary Outcome
Acute Cellular Rejection of Liver Transplant Attributed to Study Therapy
Summary
This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC
 awaiting liver transplant.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06337162
Non-Device Trial